Trial Profile

A clinical phase IIa study of Sevuparin in patients with anemia of chronic kidney disease

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 30 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Mar 2026 According to a Modus Therapeutics media release, Modus expects to have funding in place to support execution through the anticipated readout of the Phase IIa study by year-end 2026.
10 Dec 2025 According to a Modus Therapeutics media release, the first patient has been dosed in Part 2 of the ongoing Phase IIa study of sevuparin for chronic kidney disease-associated anemia, which represents the proof-of-concept phase following completion of Part 1 in Q2 2025, with single-dose safety data and future dose levels identified in Part 1 guiding Part 2, planned to begin in Q4 2025.
10 Dec 2025 Protocol amendment was submitted in summer 2025 prior to the start of Part 2 to implement final dose selection based on Part 1 data, with the first patient dosed approximately one month after regulatory approval of the amendment.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com